MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novartis AG

Gesloten

112.41 1.45

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

110.38

Max

114.32

Belangrijke statistieken

By Trading Economics

Inkomsten

-369M

2.8B

Verkoop

386M

14B

K/W

Sectorgemiddelde

18.992

63.778

EPS

1.98

Dividendrendement

3.47

Winstmarge

20.8

Werknemers

75,883

EBITDA

-426M

5.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+0.21% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.47%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

6.9B

221B

Vorige openingsprijs

110.96

Vorige sluitingsprijs

112.41

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Novartis AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2025, 06:57 UTC

Acquisities, Fusies, Overnames

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31 jan 2025, 09:49 UTC

Winsten

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31 jan 2025, 08:06 UTC

Winsten

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31 jan 2025, 06:32 UTC

Winsten

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17 mrt 2025, 07:34 UTC

Marktinformatie

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4 mrt 2025, 18:45 UTC

Winsten

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11 feb 2025, 09:25 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11 feb 2025, 06:42 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11 feb 2025, 06:22 UTC

Acquisities, Fusies, Overnames

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11 feb 2025, 06:20 UTC

Acquisities, Fusies, Overnames

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11 feb 2025, 06:19 UTC

Acquisities, Fusies, Overnames

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11 feb 2025, 06:18 UTC

Acquisities, Fusies, Overnames

Novartis: Deal Is Expected to Close in 1H of 2025

11 feb 2025, 06:18 UTC

Acquisities, Fusies, Overnames

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11 feb 2025, 06:17 UTC

Acquisities, Fusies, Overnames

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11 feb 2025, 06:16 UTC

Acquisities, Fusies, Overnames

Novartis to Buy Anthos Therapeutics for $925M Upfront

11 feb 2025, 06:15 UTC

Acquisities, Fusies, Overnames

Novartis to Buy Anthos Therapeutics

4 feb 2025, 15:16 UTC

Top Nieuws

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4 feb 2025, 08:12 UTC

Marktinformatie
Winsten

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31 jan 2025, 13:56 UTC

Winsten

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31 jan 2025, 09:59 UTC

Populaire aandelen

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31 jan 2025, 07:50 UTC

Marktinformatie

Novartis's Outlook Exceeds Market Views -- Market Talk

31 jan 2025, 07:46 UTC

Marktinformatie
Winsten

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31 jan 2025, 06:03 UTC

Winsten

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31 jan 2025, 06:02 UTC

Winsten

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31 jan 2025, 06:02 UTC

Winsten

Novartis Issues 2025 View

31 jan 2025, 06:02 UTC

Winsten

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31 jan 2025, 06:02 UTC

Winsten

Novartis 4Q Oper Pft $3.53B

31 jan 2025, 06:02 UTC

Winsten

Novartis 4Q Net Pft $2.82B

31 jan 2025, 06:02 UTC

Winsten

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31 jan 2025, 06:02 UTC

Winsten

Novartis 4Q Core Operating Profit $4.86B

Peer Vergelijking

Prijswijziging

Novartis AG Prognose

Koersdoel

By TipRanks

0.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111 USD  0.21%

Hoogste 125 USD

Laagste 97 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novartis AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

109.97 / 112.06Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.